GlassScriptPhysician profile
William Edward Anthony
NPI 1336105220
$15,381.63
in general payments reported to CMS, 2019-2025
52 companies · $2,051 in 2025
The $2,051 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,461 · 2020: $2,150 · 2021: $2,242 · 2022: $2,488 · 2023: $1,981 · 2024: $2,008 · 2025: $2,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,040.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,436.39 | 2019-2025 | |
| Abbvie INC. | $1,213.43 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Lilly USA, LLC | $1,188.17 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $970.25 | 2019-2025 | |
| Novo Nordisk INC | $893.07 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $877.88 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $811.68 | 2019-2025 | Jardiance, Synjardy |
| Janssen Pharmaceuticals, INC | $764.06 | 2019-2022 | |
| Amgen INC. | $679.86 | 2019-2025 | Otezla, Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $607.36 | 2021-2025 | |
| Astellas Pharma US INC | $522.47 | 2019-2024 | Veozah, Myrbetriq |
| Takeda Pharmaceuticals U.S.A., INC. | $475.40 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $418.76 | 2019-2025 | Xifaxan, Trulance |
| Allergan, INC. | $285.18 | 2019-2020 | |
| Glaxosmithkline, LLC. | $281.79 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $281.78 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $269.97 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $256.12 | 2023-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $256.11 | 2019-2024 | Verquvo, Capvaxive, Vaxneuvance |
| Mylan Specialty L.P. | $243.36 | 2019-2023 | Yupelri |
| Eisai INC. | $237.71 | 2019-2025 | |
| Amarin Pharma, INC. | $236.53 | 2019-2022 | |
| Kowa Pharmaceuticals America, INC. | $224.92 | 2019-2025 | Zoryve |
| Esperion Therapeutics, INC. | $217.24 | 2021-2025 | Nexletol |
| Abbott Laboratories | $182.51 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceuticals, INC. | $181.50 | 2021 | |
| Exact Sciences Corporation | $160.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $139.98 | 2019-2025 | Wavewriter Alpha Prime 16 |
| Teva Pharmaceuticals USA, INC. | $96.46 | 2019-2025 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $81.44 | 2022-2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $79.93 | 2022-2025 | Gvoke Hypopen |
| Lundbeck LLC | $78.37 | 2023-2024 | Rexulti |
| Jazz Pharmaceuticals INC. | $77.38 | 2021 | |
| Antares Pharma, INC. | $65.33 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $64.98 | 2024-2025 | Voquezna |
| Corcept Therapeutics | $61.97 | 2025 | Korlym |
| Paratek Pharmaceuticals, INC. | $60.07 | 2022-2025 | Nuzyra |
| Cequr Corporation | $59.89 | 2023-2025 | Cequr Simplicity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.08 | 2024-2025 | Caplyta |
| Genentech USA, INC. | $43.96 | 2019-2021 | |
| Dexcom, INC. | $40.37 | 2021-2024 | Dexcom G6 Transmitter |
| Sunovion Pharmaceuticals INC. | $28.17 | 2019 | |
| Shire North American Group INC | $25.79 | 2019 | |
| Shield Therapeutics INC | $21.42 | 2023 | Accrufer |
| Tris Pharma INC | $19.55 | 2019 | |
| Axsome Therapeutics, INC. | $17.17 | 2024 | Auvelity |
| Almatica Pharma LLC | $17.15 | 2022 | |
| Ibsa Pharma INC. | $16.20 | 2020 | |
| Nestle Healthcare Nutrition INC. | $14.99 | 2021 | |
| Phadia US INC. | $13.78 | 2021 | |
| Currax Pharmaceuticals LLC | $13.25 | 2020 | |
| Adlon Therapeutics L.P. | $13.13 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Anthony listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.